First-line pemetrexed-platinum doublet chemotherapy with or without bevacizumab in non-squamous non-small cell lung cancer: A real-world propensity score-matched study in China-Reference-Cited by-同舟云学术

First-line pemetrexed-platinum doublet chemotherapy with or without bevacizumab in non-squamous non-small cell lung cancer: A real-world propensity score-matched study in China

Published:2019 Issue:5 Volume:31 Page:749-758
ISSN:1000-9604
Container-title:Chinese Journal of Cancer Research
language:en
Short-container-title:

Author:

Qi Fei, ,Hu Xingsheng,Liu Yutao,Wang Zhijie,Duan Jianchun,Wang Jie,Dong Mei

Publisher

Chinese Journal of Cancer Research

Subject

Cancer Research,Oncology

Cited by 6 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. The Design for a Phase II, Randomized, Multicenter Study of CtDNA-Guided Treatment With Furmonertinib Combined Therapy or Furmonertinib Alone for Untreated Advanced EGFR Mutant Non–small-cell Lung Cancer Patients: The FOCUS-C Study;Clinical Lung Cancer;2024-06

2. Immunotherapy or antiangiogenic therapy plus chemotherapy as first‐line treatment of patients with PD‐L1(‐) advanced non‐squamous non‐small cell lung cancer in a Chinese cohort;Cancer Medicine;2023-05-22

3. Clinical efficacy and safety of maintenance therapy for advanced non-small cell lung cancer: a retrospective real-world study;World Journal of Surgical Oncology;2021-08-06

4. Pemetrexed-Platinum With or Without Bevacizumab for Chinese Chemo-Naive Advanced Lung Adenocarcinoma Patients: A Real-World Study;Frontiers in Pharmacology;2021-05-07

5. Cancer/testis antigen LDHC promotes proliferation and metastasis by activating the PI3K/Akt/GSK-3β-signaling pathway and the in lung adenocarcinoma;Experimental Cell Research;2021-01